Emergent BioSolutions (NYSE: EBS)Â has received a potential two-year, $100 million contract from the Biomedical Advanced Research and Development Authority to deliver BioThrax anthrax vaccines to the Strategic National Stockpile.
The awardÂ cameÂ three months after the Centers for Disease Control and Prevention awarded Emergent a potential $911 million follow-on contract to supply BioThrax vaccines, the company said Friday.
BioThrax or anthrax vaccine adsorbed is approved by the Food and Drug Administration for the prevention of disease caused by Bacillus anthracis.
EmergentÂ also received a modification to a potential five-year, $198.7 million contract BARDA awarded in September 2016 to advance development work on a new anthrax vaccine candidate – NuThrax – in preparation for the FDA approval process and facilitate the delivery of the vaccine to the SNS.
The contract modification calls for the company to increase the delivery of NuThrax vaccines from two million to three million doses during the contractâs base term and reduce by $100 million the purchase price for vaccine doses to be bought under the option period.
The modification will bring the total value of the contract to nearlyÂ $1.5 billion, down from the initial estimated $1.6 billion ceiling at the time of award, Emergent noted.